Hypoglycemic and hypolipidemic effects of total saponins from Stauntonia chinensis in diabetic db/db mice

J Cell Mol Med. 2018 Dec;22(12):6026-6038. doi: 10.1111/jcmm.13876. Epub 2018 Oct 16.

Abstract

Stauntonia chinensis DC. has been utilised as a traditional herbal medicine for its anti-hyperglycemic characteristic, which has been associated with triterpene saponins. The goal of the current evaluation was to examine hypoglycemic activity and affiliated mechanism of total saponins from S. chinensis. The chemical composition was analysed by HPLC-ESI-MS/MS. The fasting blood glucose, oral glucose tolerance test, insulin tolerance test, insulin and glycogen levels of type 2 diabetic db/db mice administered total saponins were quantified to determine the hypoglycemic effects. The serum lipid profiles were assessed to determine the hypolipidemic effects. Western blotting was used to quantify the protein levels of insulin receptor substrates (IRS)-1/PI3K/AKT, AMPK/ACC and GLUT4. Twenty triterpene saponins were identified from the total saponins, which exhibited hypoglycemic activities and modulated hyperlipidemia that was associated with type 2 diabetes. The hypoglycemic effects were partly due to the activation of GLUT4, which is regulated by IRS-1/PI3K/AKT. The activation of the AMPK/ACC signalling pathway may be responsible for the hypolipidemic activity. This study revealed that total saponins from S. chinensis have significant hypoglycemic and hypolipidemic activity in diabetic db/db mice, indicating that these may be utilised in the development of saponins based on S. chinensis for the treatment of type 2 diabetes.

Keywords: Stauntonia chinensis; AMPK/ACC signalling pathway; IRS-1/PI3K/Akt signalling pathway; hypoglycemic effect; hypolipidemic effect; triterpene saponins.

Publication types

  • Research Support, Non-U.S. Gov't

MeSH terms

  • AMP-Activated Protein Kinase Kinases
  • Animals
  • Blood Glucose / drug effects
  • Diabetes Mellitus, Experimental / drug therapy*
  • Diabetes Mellitus, Experimental / genetics
  • Diabetes Mellitus, Experimental / pathology
  • Diabetes Mellitus, Type 2 / drug therapy*
  • Diabetes Mellitus, Type 2 / genetics
  • Diabetes Mellitus, Type 2 / pathology
  • Glucose Tolerance Test
  • Glucose Transporter Type 4 / genetics
  • Humans
  • Hypoglycemic Agents / administration & dosage
  • Insulin / genetics
  • Insulin Receptor Substrate Proteins / genetics
  • Insulin Resistance / genetics
  • Mice
  • Mice, Inbred NOD
  • Phosphatidylinositol 3-Kinases / genetics
  • Plant Extracts / administration & dosage
  • Plant Extracts / chemistry
  • Protein Kinases / genetics
  • Proto-Oncogene Proteins c-akt / genetics
  • Ranunculales / chemistry*
  • Saponins / administration & dosage*
  • Saponins / chemistry

Substances

  • Blood Glucose
  • Glucose Transporter Type 4
  • Hypoglycemic Agents
  • Insulin
  • Insulin Receptor Substrate Proteins
  • Irs1 protein, mouse
  • Plant Extracts
  • Saponins
  • Slc2a4 protein, mouse
  • Protein Kinases
  • Proto-Oncogene Proteins c-akt
  • AMP-Activated Protein Kinase Kinases